Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial

Table 2 Child–Pugh scores at Week 8

	Patients with Child–Pugh B at Week 8, n	Patients with available BCDM-determined Child–Pugh score points, n ^a	Child–Pugh score (Week 8) n (%) ^b
	Patients with Child–Pugh B at Week 8, n		7 points	8 points	9 points
Cabozantinib	51	42	26 (51)	11 (22)	3 (6)
Placebo	22	21	11 (50)	3 (14)	5 (23)

^aTwo patients each in the cabozantinib and placebo cohorts had a score of 6. As Child–Pugh grading was investigator assessed and Child–Pugh scoring was determined independently by BCDM, some discrepancies between grading and scoring results existed. ^bPercentage of total number of patients who developed Child–Pugh B cirrhosis. BCDM Biostatistics and Clinical Data Management

ISSN: 1471-2407